Anavex Life Sciences Corp (AVXL)

[drv17]

Poster presentation:

P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the
Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP1
, Michael Kornhauser BPharm1
, Ella Modini BSc1
, Harald Hampel, MD PhD2
, Stephan Toutain MS3
,
Christopher Missling PhD3
1
HammondCare Dementia Centre, NSW, Australia, 2Sorbonne University, Paris, France, 3
Anavex Life Sciences Corp., New York, USA

It is good to see that the posters will be available for the entire conference instead of just a single day providing an opportunity for attendees (and media ) to review those of interest they might have missed.

Coffee Breaks and Poster Sessions:
Breaks and poster presentations will be held in the dedicated area across from the auditorium. This year all posters for all the different themes will be presented during the entire conference. Meet our poster presenters during the coffee breaks.

CTAD 2018 Program